R&D News | pharmaphorum

News

Gilead licenses Jounce immunotherapy for $800m

Gilead has joined forces with biotech Jounce Therapeutics to licence its immunotherapy JTX-1811 in a deal worth more than $800 million.

News

MHRA publishes guidance on medicine regulation after Brexit

The UK’s medicines regulator has published long-awaited guidance on regulation of medicines and medical devices as the UK approaches the end of its Brexit transition period at the end of th

News

GSK and Vir take COVID-19 antibody therapy into clinic

GlaxoSmithKline and US-based Vir Biotechnology are to trial a new therapy for COVID-19 based on an antibody designed to neutralise the SARS-CoV-2 coronavirus.

News

AZ expands phase 3 trials of COVID-19 vaccine frontrunner in...

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups.

News

Sanofi/Regeneron's Kevzara fails again in serious COVID-19 c...

Sanofi has drawn another blank in its attempt to repurpose its IL-6 drug Kevzara to tackle the extreme immune reaction seen in serious cases of COVID-19.

News

AZ trumpets Farxiga survival data in renal disease at ESC 20...

AstraZeneca’s Farxiga is already ahead of rivals in the SGLT2 inhibitor field in heart failure, and now looks set to repeat that success in renal disease after reporting stella

Gilead licenses Jounce immunotherapy for $800m

MHRA publishes guidance on medicine regulation after Brexit

GSK and Vir take COVID-19 antibody therapy into clinic

AZ expands phase 3 trials of COVID-19 vaccine frontrunner in...

Sanofi/Regeneron's Kevzara fails again in serious COVID-19 c...

AZ trumpets Farxiga survival data in renal disease at ESC 20...

Hengrui gets world-first okay for platelet drug hetrombopag

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks